2-(3-Propan-2-yl-1,2-oxazol-5-yl)acetic acid | 1024606-08-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(3-Propan-2-yl-1,2-oxazol-5-yl)acetic acid
• CAS: 1024606-08-3
• 化学式: C₈H₁₁NO₃
• 分子量: 169.18
• InChiKey: WTVQJIVEVKJGTP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  63.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(3-Propan-2-yl-1,2-oxazol-5-yl)acetic acid 、 2-氨基-5-氯二苯甲酮 在 三氯氧磷 作用下， 生成 5-(2,6-Dichloro-4-phenylquinolin-3-yl)-3-propan-2-yl-1,2-oxazole
  参考文献：
  名称：

  Synthesis and evaluation of novel 3,4,6-substituted 2-quinolones as FMS kinase inhibitors

  摘要：

  A series of 3,4,6-substituted 2-quinolones has been synthesized and evaluated as inhibitors of the kinase domain of macrophage colony-stimulating factor-1 receptor (FMS). The fully optimized compound, 4-(4-ethyl-phenyl)-3-(2-methyl-3H-imidazol-4yl)-2-quinolone-6-carbonitrile 21b, has an IC50 of 2.5 nM in an in vitro assay and 5.0 nM in a bone marrow-derived macrophage cellular assay. Inhibition of FMS signaling in vivo was also demonstrated in a mouse pharmacodynamic model. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.01.088

文献信息

• SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS
  申请人：Das Jagabandhu

  公开号：US20130158001A1

  公开（公告）日：2013-06-20

  Disclosed are compounds of Formula (I): (I) or stereoisomers, salts, or prodrugs thereof, wherein: (i) R1 and R2 are independently C 1 -C 4 alkyl, or (ii) R 1 and R 2 together with the carbon atom to which they are attached, form a cyclic group; and Q is H, C 1-6 alkyl, phenyl or 5- to 6-membered heteroaryl substituted with zero to 3 substituents, and G is defined herein. Also disclosed are method of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. There compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and chronic inflammatory disease.

  本发明涉及式(I)的化合物：(I)或其立体异构体、盐或前药，其中：(i) R1和R2独立地是C1-C4烷基，或者(ii) R1和R2与它们连接的碳原子一起形成一个环状基团；Q为H、C1-6烷基、苯基或5-到6-成员杂环芳基取代零至3个取代基，G在此定义。还公开了使用这些化合物作为选择性G蛋白偶联受体S1P1激动剂的方法，以及包含这些化合物的制药组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或疾病中是有用的，例如自身免疫性疾病和慢性炎症性疾病。
• US8178681B2
  申请人：——

  公开号：US8178681B2

  公开（公告）日：2012-05-15
• US8367666B2
  申请人：——

  公开号：US8367666B2

  公开（公告）日：2013-02-05
• US8822510B2
  申请人：——

  公开号：US8822510B2

  公开（公告）日：2014-09-02